Identification of prognostic factors in post-transplantation lymphoproliferative disorders;Identification de facteurs pronostiques dans les lymphoprolifé rations post-transplantation

Bulletin du Cancer

Volumn 91, Issue 4, 2004, Pages 373-378

  Choquet, Sylvain ^a   Levy, Vincent ^b   Leblond, Véronique ^c  

^a CENTRE HOSPITALIER DE VERSAILLES   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

IPI; Organ transplantation; Post transplantation lymphoproliferative disorder; Prognostic factor

Indexed keywords

AZATHIOPRINE; BLEOMYCIN; CD24 ANTIGEN; CHLORMETHINE; CISPLATIN; COMPLEMENT COMPONENT C3D RECEPTOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; ORGAN TRANSPLANTATION; PROGNOSIS; RADIODENSITOMETRY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; FEMALE; HEALTH STATUS; HUMANS; IMMUNOCOMPETENCE; LYMPHOMA, NON-HODGKIN; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 2442650062     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995 ; 85 : 552-65.
2. Harris NL, Swerdlow SH, Frizzera G, Knowles DM. In : Jaffe ES, Harris NL, Stein H, Vardlman JW, eds. World Health Organization Classification of tumours : pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press 2001 ; 264-9.
3. Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, Sutton L et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus : a distinct entity ? J Clin Oncol 1998 ; 16 : 1-9.
4. Timms JM, Bell A, Flavell JR, Murray PG, Rickinson AB, Traverse-Glehen A, et al. Target cells of Epstein-Barr-virus (EBV)-positive posttransplant lymphoproliferative disease : similarities to EBV-positive Hodgkin's lymphoma. Lancet 2003 ; 361 : 217-23.
5. The international Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993 ; 329 : 1219-24.
6. Armitage JM, Kormos RL, Stuart RS, Fricker FJ, Griffith BP, Nalesnik M et al. Post-transplant lymphoproliferative disease in thoracic organ transplant patients : ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991 ; 10 : 877-87.
7. Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA et al. The pathology of posttransplant lymphoproliferative diorders occuring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988 ; 133 : 173-92.
8. Benkerrou M, Jais JP, Leblond V, Durandy A, Sutton L, Bordigoni P et al. Anti-B-cell monoclonal antibody treatment of severe posttranplant B-lymphoproliferative disorders : prognostic factors and long-term outcome. Blood 1998; 92: 3137-47.
9. Choquet S, Leblond V, Milpied N, Herbrecht R, Fischer A, Salles G et al. Efficacy and safety of rituximab in B-cell post transplantation lymphoproliferative disorders (B-PTLD) : final results of a multicenter, open label, phase II trial (M39037 trial). American Society of Haematology, San Diego, USA, décembre 2003, abstract 98.
10. Penn I, Porat G. Central nervous system in organ allograft recipients. Transplantation 1995 ; 59 : 240-4.
11. Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995 ; 86 : 3333-40.
12. Garrett TJ, Chadburn A, Barr ML, Drusin RE, Chen JM, Schulman LL et al. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. Cancer 1993 ; 72: 2782-5.
13. Choquet S, Oertel S, Leblond V, Riess H, Levy V, Raphael M et al. European Society of Haematology, Lyon, France, 2003, abstract 324.
14. Horwitz SM, Ranheim EA, Morgan DS. A unified approach to posttransplant lymphoproliferative disorder (PTLD) : improved outcome and analysis of prognostic factors. Blood 1999 ; 94 (suppl. 1) : abstract 2295.
15. Chadburn A, Chen JM, Hsu DT, Frizzera G, Cesarman E, Garrett TJ et al. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Cancer 1998 ; 82 : 1978-87.
16. Habermann TM, ansell SM, Velosa JA. Posttransplant lymphoproliferative disorders (PTLD) : long-term outcome and prognostic factors. Blood 1999 ; 94 (suppl. 1) : abstract 2296.
17. Choquet S, Leblond V, Levy V, Raphael M, Barrou V, Davi F et al. Post-transplant lymphoproliferative disorders (PTLD) : a monocentric clinicopathologic study of 71 cases. Lugano, Suisse, 2002, abstract 276.
18. Harris NL, Ferry JA, Swerdelow SH. Posttransplant lymphoproliferative disorders : summary of Society for Hemathopathology Workshop. Semi Diagn Pathol 1997 ; 14 : 8-14.